0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
INFLUENTIAL PUBLICATIONS   |    
Bibliography Bipolar Disorder
FOCUS 2007;5:40-43.
View Author and Article Information

Copyright 2007 American Psychiatric Association

text A A A

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

Papadimitriou GN, Dikeos DG, Soldatos CR, Calabrese JR: Non-pharmacological treatments in the management of rapid cycling bipolar disorder. J Affect Disord2007; 98:1—10

Albanese MJ, Clodfelter RC Jr, Pardo TB, Ghaemi SN: Underdiagnosis of bipolar disorder in men with substance use disorder. J Psychiatr Pract2006; 12:124—127

Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II, Duhamel KN: Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract2006; 12:269—282

Altshuler LL, Post RM, Black DO, Keck PE, Nolen WA, Frye MA, Suppes T, Grunze H, Kupka RW, Leverich GS, McElroy SL, Walden J, Mintz J: Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry2006; 67:1551—1560

Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL, Grunze H, Kitchen CM, Post R: Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry2006; 163:313—315

Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J: Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord2006; 8:625—639

Ball JR, Mitchell PB, Corry JC, Skillecorn A, Malhi GS: A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry2006; 67: 277—286

Birmaher B, Axelson D, Strober M, Gill MK, Valeri S, Chiappetta L, Ryan N, Leonard H, Hunt J, Iyengar S, Keller M: Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry2006; 63: 175—183

Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry2006; 163:1199—1201

Findling RL, McNamara NK, Stansbrey R, Gracious BL, Whipkey RE, Demeter CA, Reed MD, Youngstrom EA, Calabrese JR: Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization. J Am Acad Child Adolesc Psychiatry2006;45:142—148

Frye MA, Calabrese JR, Reed ML, Hirschfeld RM: Healthcare resource utilization in bipolar depression compared with unipolar depression: results of a United States population-based study. CNS Spectr2006; 11: 704—710

Gitlin M: Treatment-resistant bipolar disorder. Mol Psychiatry2006; 11:227—240

Green EK, Raybould R, Macgregor S, Hyde S, Young AH, O’Donovan MC, Owen MJ, Kirov G, Jones L, Jones I, Craddock N: Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder—case-control study of over 3000 individuals from the UK. Br J Psychiatry2006; 188: 21—25

Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry2006; 67:95—101

Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry2006; 163:232—239

Miklowitz DJ: An update on the role of psychotherapy in the management of bipolar disorder. Curr Psychiatry Reports2006; 8:498—503
Role of Psychotherapy in the Management of Bipolar DisorderONLINE EXCLUSIVE: Full text of article as it originally appeared.

Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry2006; 163:210—216

Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder. Am J Psychiatry2006; 163:217—224. Reprinted in FOCUS 2006; 4:553—561

Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry2006; 67:509—516

Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CM, Mintz J: Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry2006; 189:124—131

Post RM, Leverich GS: The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention. Dev Psychopathol2006; 18:1181—1211

Scott J: Psychotherapy for bipolar disorders—efficacy and effectiveness. J Psychopharmacol2006; 20(2 suppl):46—50

Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H: Cognitive-behavioural therapy for severe and recurrent bipolar disorders—randomised controlled trial. Br J Psychiatry2006; 188:313—320

Simon GE, Ludman EJ, Bauer MS, Unutzer J, Operskalski B: Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry2006; 63:500—508

Thase ME: Bipolar depression: Diagnostic and treatment considerations. Dev Psychopathol2006; 18:1213—1230

Thase ME: Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep2006; 8:478—488
Pharmacotherapy of Bipolar DepressionONLINE EXCLUSIVE: Full text of article as it originally appeared.

Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JCY, Bowden CL: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry2006; 163: 247—256

Weisler RH, Cutler AJ, Ballenger JC, Post RM, Ketter TA: The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr2006; 11:788—799

Bowden CL, Collins MA, McElroy SL, Calabrese JR, Swann AC, Weisler RH, Wozniak PJ: Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology2005; 30:1932—1939

Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry2005; 66: 111—121

Calabrese JR, Keck PE Jr, Bowden CL, Ketter TA, Sachs G, Findling RL, Sajatovic M: A US perspective of the CANMAT bipolar guidelines. Bipolar Disord2005; 7(suppl 3):70—72

Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry2005; 162:1351—1360

Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, Grochocinski V, Houck P, Scott J, Thompson W, Monk T: Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry2005; 62: 996—1004

Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O, Calabrese JR, Grunze H: Antiepileptic drugs in mood-disordered patients. Epilepsia2005;46(suppl 4): 38—44

Gao K, Gajwani P, Elhaj O, Calabrese JR: Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry2005; 66:1376—1385

Havens LL, Ghaemi SN: Existential despair and bipolar disorder: the therapeutic alliance as a mood stabilizer. Am J Psychother2005; 59:137—147

Hirschfeld RMA: Guideline watch: Practice guideline for the treatment of patients with bipolar disorder, 2nd edition. Arlingon, VA, American Psychiatric Association, 2005

Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O’Keeffe CM, Schumacher MR. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry2005; 66:642—645

Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M: Risperidone in the treatment of acute bipolar mania: double-blind, placebo-controlled study. Br J Psychiatry2005; 187:229—234

McIntyre RS, Brecher M, Paulsson B, Huziar K, Mullen J: Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol2005; 15:573—585

Michalak EE, Yatham LN, Lam RW: Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes2005; 3:72

Potkin SG, Keck PE Jr, Segal S, Ice K, English P: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol2005; 25:301—310

Quanbeck CD, McDermott BE, Frye MA: Clinical and legal characteristics of inmates with bipolar disorder. Curr Psychiatry Rep2005; 7:478—484

Simeonova DI, Chang KD, Strong C, Ketter TA: Creativity in familial bipolar disorder. J Psychiatr Res2005; 39:623—631

Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F: Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol2005; 15:75—84

Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC, Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry2005; 66:870—886

Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell’Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry2005; 162:1281—1290

Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T: Effectiveness of aripiprazole vs haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry2005; 187: 235—242

Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry2005; 66: 323—330

Yatham LN, Kennedy SH, O’Donovan C, Parikh S, Macqueen G, Mcintyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Milev R, Young T, Ravindran A, Schaffer A, Connolly M, Gorman CP: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord2005; 7(suppl 3):5—69

Bauer MS, Mitchner L: What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry2004; 161:3—18

Calabrese JR, Hirschfeld RM, Frye MA, Reed ML: Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry2004; 65: 1499—1504

Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry2004; 65:432—441

Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry2004; 161:1057—1065

Nolen WA, Luckenbaugh DA, Altshuler LL, Suppes T, McElroy SL, Frye MA, Kupka RW, Keck PE Jr, Leverich GS, Post RM. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry2004; 161:1447—1454

Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE: Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord2004; 6:213—223

Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry2004; 184:337—345

Zarate CA Jr, Tohen M: Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry2004; 161:169—171

Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry2003; 60:392—400

Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry2003; 64:1013—1024

Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J: A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry2003; 60: 402—407

Duffy A, Grof P, Robertson C, Alda M.Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J., Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand. 2003; 108:4—14

Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA2003; 290:1467—1473

Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD: Screening for bipolar disorder in the community. J Clin Psychiatry2003; 64: 53—59

Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry2003; 160:1651—1658

Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry2003; 160:741—748

Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P: A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry2003; 60:145—152

Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL: A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry2003; 60:904—912

Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry2003; 160:1263—1271

Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry2003; 60:1079—1088

Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry2003; 182:141—147

Hirschfeld RM, Bowden CL, Gitlin MJ, Keck PE, Perlis RH, Suppes T, Thase ME, Wagner KD: American Psychiatric Association practice guideline for the treatment of patients with bipolar disorder (revision) Focus2003; 1:1—50. Reprinted in FOCUS 2003; 1: 64—110

Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry2002; 59:530—537

Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry2002; 159:1146—1154

Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry2002; 159: 1011—1017

Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry2002; 59:62—69

Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry2002; 63:508—512

Angst J, Marneros A: Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord2001; 67:3—19

Altshuler LL, Hendrick V, Cohen LS: An update on mood and anxiety disorders during pregnancy and the postpartum period. Prim Care Companion J Clin Psychiatry2000; 2:217—222

Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J: Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry2000; 157:1873—1875

Benazzi F: Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord1997; 43:163—166

+

References

+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
APA Practice Guidelines > Chapter 7.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
APA Practice Guidelines > Chapter 0.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 5.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines